Exosomal delivery of NF-κB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models

Sci Adv. 2021 Jan 22;7(4):eabd3865. doi: 10.1126/sciadv.abd3865. Print 2021 Jan.

Abstract

Accumulation of immune cells and activation of the pro-inflammatory transcription factor NF-κB in feto-maternal uterine tissues is a key feature of preterm birth (PTB) pathophysiology. Reduction of the fetal inflammatory response and NF-κB activation are key strategies to minimize infection-associated PTB. Therefore, we engineered extracellular vesicles (exosomes) to contain an NF-κB inhibitor, termed super-repressor (SR) IκBα. Treatment with SR exosomes (1 × 1010 per intraperitoneal injection) after lipopolysaccharide (LPS) challenge on gestation day 15 (E15) prolonged gestation by over 24 hours (PTB ≤ E18.5) and reduced maternal inflammation (n ≥ 4). Furthermore, using a transgenic model in which fetal tissues express the red fluorescent protein tdTomato while maternal tissues do not, we report that LPS-induced PTB in mice is associated with influx of fetal innate immune cells, not maternal, into feto-maternal uterine tissues. SR packaged in exosomes provides a stable and specific intervention for reducing the inflammatory response associated with PTB.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Female
  • Fetus
  • Humans
  • Infant, Newborn
  • Inflammation / metabolism
  • Lipopolysaccharides* / adverse effects
  • Mice
  • NF-kappa B / metabolism
  • Pregnancy
  • Premature Birth* / metabolism
  • Uterus / metabolism

Substances

  • Lipopolysaccharides
  • NF-kappa B